Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522

Journal of Urology

Volumn 172, Issue 4 I, 2004, Pages 1474-1479

  Mizutani, Yoichi ^a   Nakanishi, Hiroyuki ^a   Li, Yong Nan ^a   Sato, Nodoka ^a   Kawauchi, Akihiro ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

4 (4 cyclohexyl 2 methyloxazol 5 yl) 2 fluorobenzenesulfonamide; Apoptosis; Bladder; Bladder neoplasms; Cyclooxygenase 2

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; METHOTREXATE; PROTEIN BCL 2; TILMACOXIB; TRANSPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; XENOTRANSPLANTATION;

EID: 4544350587     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000131945.74377.ad     Document Type: Article

References (20)

1. Taketo, M. M.: Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst, 90: 1529, 1998
2. Masferrer, J. L., Zweifel, B. S., Manning, P. T., Hauser, S. D., Leahy, K. M., Smith, W. G. et al: Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and non-ulcerogenic. Proc Natl Acad Sci USA, 91: 3228, 1994
3. Taketo, M. M.: Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst, 90: 1609, 1998
4. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E. et al: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803, 1996
5. Shirahama, T., Arima, J., Akiba, S. and Sakakura, C.: Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer, 92: 188, 2001
6. Mizutani, Y., Yoshida, O., Miki, T. and Bonavida, B.: Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin Cancer Res, 5: 2605, 1999
7. Mizutani, Y., Nakao, M., Ogawa, O., Yoshida, O., Bonavida, B. and Miki, T.: Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand-mediated apoptosis by cisplatin and carboplatin. J Urol, 165: 263, 2001
8. Wakitani, K., Nanayama, T., Masaki, M. and Matsushita, M.: Profile of JTE-522 as a human cyclooxygenase-2 inhibitor. Jpn J Pharmacol, 78: 365, 1998
9. Mizutani, Y., Bonavida, B., Koishihara, Y., Akamatsu, K., Ohsugi, Y. and Yoshida, O.: Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6-receptor monoclonal antibody. Cancer Res, 55: 590, 1995
10. Mizutani, Y., Okada, Y., Yoshida, O., Fukumoto, M. and Bonavida, B.: Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity. Cancer, 79: 1180, 1997
11. Seibert, K., Lefkowith, J., Tripp, C., Isakson, P. and Needleman, P.: COX-2 inhibitors-is there cause for concern. Nat Med, 5: 621, 1999
12. FitzGerald, G. A. and Patrono, C.: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med, 345: 433, 2001
13. Zhang, L., Yu, J., Park, B. H., Kinzler, K. W. and Vogelstein, B.: Role of BAX in the apoptotic response to anticancer agents. Science, 290: 989, 2000
14. Liu, X. H., Yao, S., Kirschenbaum, A. and Levine, A. C.: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res, 58: 4245, 1998
15. Oltvai, Z. N., Milliman, C. L. and Korsmeyer, S. J.: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609, 1993
16. Connors, T. A., Cleare, M. J. and Harrap, K. R.: Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat Rep, 63: 1499, 1979
17. Zwelling, L. A., Kohn, K. W., Ross, W. E., Ewig, R. A. and Anderson, T.: Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and trans-diamminedichloroplatinum (II). Cancer Res, 38: 1762, 1978
18. Kishi, K., Petersen, S., Petersen, C., Hunter, N., Mason, K., Masferrer, J. L. et al: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res, 60: 1326, 2000
19. Ferrario, A., von Tiehl, K., Wong, S., Luna, M. and Gomer, C. J.: Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res, 62: 3956, 2002
20. Kerr, J. F., Winterford, C. M. and Harmon, B. V.: Apoptosis. Its significance in cancer and cancer therapy. Cancer, 73: 2013, 1994